GSK plc vs iShares MBS ETF — how do they compare? GSK plc trades at $50.39 (market cap $102.60B), while iShares MBS ETF trades at $93.26. The key difference: GSK plc pays a 3.57% dividend while iShares MBS ETF pays none, and GSK plc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| GSK | MBB | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $96.91 |
52-Week Low | $38.22 | $92.72 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
MBB trades at $93.28, up 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments of $0.33-$0.34 per share in mid-2026. Focus Financial Network increased its stake by 13.8% in the latest quarter, holding 49,056 shares as of its most recent SEC filing.
The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Key risks include market volatility and reliance on institutional interest. Investment opportunities hinge on dividend income and potential institutional accumulation, but the lack of current financial metrics warrants careful evaluation.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →